July 13, 2026 10:55 AM GMT Cosmos Pharmaceutical (3349) | Japan M Update F5/26 Results: OP +18% YoY; Results/Plan In Line with Market Expectations Reaction to earnings Key Takeaways Unchanged In-line Largely unchanged Impact to our thesis Financial results versus consensus Direction of next 12-month consensus EPS Source: Company data, Morgan Stanley Research Results: F5/26 4Q GPM was 20.7% (-0.2ppt YoY, +0.6ppt vs. three years ago), broadly in line with historical trends. Key takeaways from the management m ...